Novel inhibitor against Rac1 for therapeutic approach in prevention of breast cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic breast cancer poses a significant mortality risk, often due to dormant cancer cells.
• Rac1 protein is crucial in cancer metastasis, regulating cell structures like lamellipodia and filopodia.

Purpose of the Study:

• To develop and evaluate a novel peptide inhibitor, FGDWS, targeting the Rac1-Tiam1 binding site for metastatic breast cancer treatment.
• To assess the efficacy of FGDWS alone and in combination with Doxorubicin (Dox) in preclinical models.

Main Methods:

• In-silico screening identified FGDWS as a potent inhibitor of Rac1-Tiam1 interaction.
• Surface Plasmon Resonance (SPR) and MTT assays confirmed peptide binding and cell viability reduction.
• In vitro studies included cell migration, apoptosis assays (Annexin-V, caspase 3/7), and Western blot.
• In vivo studies utilized a mice model for tumor regression experiments.

Main Results:

• FGDWS demonstrated strong binding to Rac1 and significantly reduced breast cancer cell viability.
• The peptide suppressed cancer cell migration and induced apoptosis.
• Combination therapy with Doxorubicin showed synergistic effects, enhancing tumor regression and apoptosis.
• Tumor size was significantly reduced in mice treated with FGDWS, with greater reduction in the combination group.

Conclusions:

• The peptide FGDWS is a promising novel inhibitor targeting Rac1 in metastatic breast cancer.
• Combination therapy of FGDWS with Doxorubicin may offer enhanced treatment efficacy with potentially reduced side effects.
• Further investigation into the synergistic mechanisms and clinical translation is warranted.